Caterpillar Inc vs Davita Inc — how do they compare? Caterpillar Inc trades at $936.8 (market cap $429.89B), while Davita Inc trades at $232 (market cap $14.92B). The key difference: Caterpillar Inc is far larger — about 28.8× Davita Inc's market cap, and Caterpillar Inc pays a 0.7% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| CAT | DVA | |
|---|---|---|
Market Cap | $429.89B | $14.92B |
Sector | Industrials | Health |
52-Week High | $1.06K | $235.71 |
52-Week Low | $404.64 | $103.87 |
Enterprise Value | $468.88B | $27.47B |
Dividend Yield | 0.7% | — |
Signals from Pluang's Aura AI — not financial advice
Caterpillar (CAT) trades at $933.34, down 2.0% on the day but up 51% year-to-date, reflecting strong momentum from AI-driven infrastructure demand. The company has beaten earnings estimates for three consecutive quarters, with Q1 2026 EPS of $5.54 surpassing expectations by 19%. Valuation metrics remain elevated with a P/E of 46.39 and P/S of 6.18, while profitability remains robust with a 13.33% net margin and 51.35% ROE. Technical indicators show neutral signals with support at $922 and resistance at $943.
Outlook remains positive with analyst consensus pointing to $1,020 price target (9% upside) and 55% buy ratings. Key opportunities include AI data center power demand generating $10.2B in generator sales, while risks include elevated valuation and cyclical exposure to economic conditions. The company's 32nd consecutive dividend increase expected in June supports income investors.
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
Trailing returns across standard periods
Caterpillar Inc. designs, manufactures, and markets construction, mining, and forestry machinery. The Company also manufactures engines and other related parts for its equipment, and offers financing and insurance. Caterpillar distributes its products through a worldwide organization of dealers.
Read more on CAT →DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →